红楼春上春快播,《妽妽的丰满大胸》1,慈禧秘史邱淑贞

來曲珠利

NMR下載 COA and HPLC MSDS下載
names：
Letrazuril
CAS號：
103337-74-2
MDL Number： MFCD00867212
MF(分子式)： C17H9Cl2FN4O2 MW(分子量)： 391.18
EINECS:No data available Reaxys Number:No data available
Pubchem ID:59745 Brand:BIOFOUNT

來曲珠利(103337-74-2,Letrazuril)是一種抗艾滋病毒的化合物。Letrazuril已用于研究治療HIV感染和隱孢子蟲病的試驗中。

貨品編碼	規格	純度	價格 (￥)	現價(￥)	特價(￥)	庫存描述	數量	總計 (￥)
YZM000672-5mg	5mg	98.27%	￥ 3543.00	￥ 3543.00		2-3天	- +	￥ 0.00
YZM000672-1mg	1mg	98.27%	￥ 1462.50	￥ 1462.50		2-3天	- +	￥ 0.00

大包裝詢價提供各種包裝，敬請垂詢
收藏商品商品點評加入購物車立即購買

快速詢價

收起

你想詢價的產品

*產品名稱：

CAS號：

產品編號：

需求描述：

請準確填寫您的聯系方式，以便為您提供最好的服務。

*公司名稱：

*電子郵箱：

聯系人：

*電話：

*驗證碼：

詢價

中文別名	來曲珠利(103337-74-2); 左沙丁胺;
英文別名	Letrazuril(103337-74-2);LETRAZURIL;Letrazurilo; Letrazurilum; AC1L1RUW; AC1Q4NLM;
CAS號	103337-74-2
Inchi	InChI=1S/C17H9Cl2FN4O2/c18-13-5-11(24-17(26)23-15(25)8-22-24)6-14(19)16(13)12(7-21)9-1-3-10(20)4-2-9/h1-6,8,12H,(H,23,25,26)
InchiKey	XQKYUBTUOHHNDV-UHFFFAOYSA-N
分子式 Formula	C17H9Cl2FN4O2
分子量 Molecular Weight	391.18
溶解度Solubility	生物體外In Vitro:DMSO溶解度≥ 165 mg/mL(421.80 mM)*"≥" means soluble可溶, but saturation unknown溶解度未知.
性狀	固體粉末,Power
儲藏條件 Storage conditions	-20°C 3 years年 4°C 2 years年 / In solvent溶液中:-80°C 6 months月 -20°C 1 month月

來曲珠利(103337-74-2,Letrazuril)實驗注意事項：
1.實驗前需戴好防護眼鏡，穿戴防護服和口罩，佩戴手套，避免與皮膚接觸。
2.實驗過程中如遇到有毒或者刺激性物質及有害物質產生，必要時實驗操作需要手套箱內完成以免對實驗人員造成傷害
3.實驗后產生的廢棄物需分類存儲，并交于專業生物廢氣物處理公司處理，以免造成環境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tags：來曲珠利試劑,來曲珠利雜質,來曲珠利中間體,來曲珠利密度,來曲珠利結構式,來曲珠利溶解度,來曲珠利合成,來曲珠利閃點,來曲珠利購買,來曲珠利MSDS,

產品說明	來曲珠利(103337-74-2,Letrazuril)是一種有效的抗HIV的有機化合物
Introduction	(來曲珠利,103337-74-2)Letrazuril is anantiIVagent.
Application1	來曲珠利(103337-74-2,Letrazuril)是一種抗艾滋病毒的化合物。Letrazuril已用于研究治療HIV感染和隱孢子蟲病的試驗中。
Application2
Application3

來曲珠利(103337-74-2,Letrazuril)藥理學：

來曲珠利(103337-74-2,Letrazuril)是一種抗艾滋病毒的化合物。Letrazuril已用于研究治療HIV感染和隱孢子蟲病的試驗中。

警示圖
危險性	warning
危險性警示	Not available
安全聲明	H303吞入可能有害+H313皮膚接觸可能有害+H2413吸入可能對身體有害
安全防護	P264處理后徹底清洗+P280戴防護手套/穿防護服/戴防護眼罩/戴防護面具+P305如果進入眼睛+P351用水小心沖洗幾分鐘+P338取出隱形眼鏡（如果有）并且易于操作,繼續沖洗+P337如果眼睛刺激持續+P2393獲得醫療建議/護理
備注	實驗過程中防止吸入、食入，做好安全防護

A Study of Letrazuril in the Treatment of AIDS-Related Diarrhea Phase 1 Completed 2005-06-24

Hamour AA, et al. Successful treatment of AIDS-related cryptosporidial sclerosing cholangitis. AIDS. 1993 Nov;7(11):1449-51.

Letrazuril shows potential in AIDS-related cryptosporidiosis Inpharma Weekly 1994

Oral nitazoxanide and paromomycin inhalation for systemic cryptosporidiosis in a patient with AIDS Infection 1999

Chemotherapy of human and animal coccidioses: state and perspectives Parasitology Research 1996

來曲珠利(103337-74-2,Letrazuril)參考文獻：

1、Treatment with letrazuril of refractory cryptosporidial diarrhea complicating AIDS M Loeb 1, C Walach, J Phillips, I Fong, I Salit, A Rachlis, S Walmsley

Abstract：Thirty-five AIDS patients (mean CD4 count 44 x 10(6)/L) with chronic cryptosporidiosis were treated with letrazuril at an initial oral daily dose of 50 mg in an open-label Phase I prospective trial. Treatment was continued for > or = 10 days and for as long as there was a response. The majority of subjects (91%), had previously failed paromomycin treatment. At baseline, 74% of patients had moderate (five to nine bowel movements per day) to severe (> 10 bowel movements per day) diarrhea. Twenty-three subjects (66%) had a clinical response within a mean of 1.7 weeks of treatment initiation. Twenty-two patients had a partial response (> 50% reduction in bowel movements per day for > or = 1 week), one patient had a complete response (two or fewer bowel movements per day). Of the responders, 15 (65%) had a clinical relapse with worsening diarrhea at an average of 1.2 months following initiation of letrazuril. The other eight (35%) had had symptom control for an average of 2.9 months from initiation of letrazuril to the latest follow-up. Microbiologic eradication was demonstrated in 10 (40%) of 25 patients with follow-up stool examinations. Seven patients (20%) experienced a rash, all within 1 week of starting the drug, and resolved in all patients when the drug was discontinued. In conclusion, severely immunocompromised AIDS patients with refractory cryptosporidiosis may show a modest, short-lived response to letrazuril. Microbiologic response is variable and relapse high. Rash is a major limiting side effect of the drug.

2、Pilot studies of azithromycin, letrazuril and paromomycin in the treatment of cryptosporidiosis C Blanshard 1, D C Shanson, B G Gazzard

Abstract：Pilot studies of the safety and efficacy of 3 drugs thought to have anticryptosporidial activity were carried out to determine whether any of them are suitable for large-scale clinical trials. Open studies of the use of azithromycin, letrazuril and paromomycin in patients with acquired immunodeficiency syndrome (AIDS) and confirmed cryptosporidial diarrhoea for at least a month. Azithromycin 500 mg daily was ineffective. Letrazuril 150-200 mg daily was associated with an improvement in symptoms in 40% of patients treated and cessation of excretion of cryptosporidial oocysts in the stool in 70%; however biopsies remained positive. Paromomycin therapy was associated with a complete resolution of diarrhoea in 60% of patients treated and some improvement in symptoms in a further 5% but it did not eliminate the infection. None of the drugs had any major toxicities. Dose escalation studies of azithromycin should be performed. Letrazuril should be further investigated for efficacy in double-blind placebo-controlled trials. Paromomycin appears to result in prolonged symptomatic remission of cryptosporidial diarrhoea, but has no effect on cryptosporidial cholangitis.

對不起，暫無產品評價！

MSDS

SDS 1.0 中文

展開

SDS 1.0 英文

展開